Klotho Benefits: What Studies Report

Klotho is discussed in the literature as a protein family rather than as a therapeutic peptide product. A 2019 review in Nature Reviews Nephrology described the klotho proteins — α-klotho, β-klotho and γ-klotho — as membrane and circulating proteins that act as co-receptors for fibroblast growth factors and examined their roles across health and disease states (PMID 30455427). That framing matters for anyone reading "klotho benefits" content: much of what is attributed to klotho in popular summaries is actually evidence about the FGF23 and FGF21 signalling systems in which klotho participates. For background on the protein itself, see the klotho overview.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition, laboratory result or treatment decision. Nothing here describes a protocol, and no product is recommended, endorsed or offered.

How the evidence tiers break down

Published klotho work falls into three broad categories, and mixing them is the most common source of overstatement. Narrative and mechanistic reviews summarise biology; animal and cell experiments test manipulation of klotho or its signalling partners; and human studies are, in the papers summarised here, observational rather than interventional. A 2024 observational analysis in adults with cardiovascular-kidney-metabolic syndrome, for example, reported associations between serum klotho concentrations and both disease severity and mortality, which is an association and not a demonstration that raising klotho changes outcomes (PMID 39695774).

Kidney function and kidney aging

The kidney is where klotho research is densest. A 2020 review in Frontiers in Endocrinology addressed klotho in the context of aging and the failing kidney, placing the protein within the biology of declining renal function (PMID 32982966). A separate 2018 review of the aging kidney and aging-related disease discussed how age-associated structural and functional kidney changes intersect with systemic disease (PMID 30232759). The 2019 klotho review likewise considered kidney disease among the conditions in which klotho biology has been studied (PMID 30455427).

What researchers reported in these papers is a relationship, not a treatment result. None of the cited kidney papers described a randomised human trial in which klotho was administered and hard renal endpoints improved. Readers encountering claims that klotho "restores kidney function" should note that the cited literature frames klotho as a biomarker and mechanistic participant rather than as an established intervention (PMID 32982966).

Cardiovascular and vascular outcomes

A 2024 review in Nature Reviews Cardiology examined FGF23 and klotho at the intersection of kidney and cardiovascular disease, drawing together the signalling biology that links mineral handling with cardiac and vascular pathology (PMID 37443358). The 2024 observational study in cardiovascular-kidney-metabolic syndrome reported that serum klotho measurements tracked with severity and mortality in that adult population (PMID 39695774).

Observational associations of this kind cannot separate cause from consequence: lower circulating klotho may reflect kidney and vascular disease rather than drive it, a limitation the review literature on the FGF23–klotho axis has emphasised (PMID 37443358). No cited paper reported a cardiovascular outcome trial of klotho administration in humans.

Blood pressure and phosphate

A 2019 review in Current Opinion in Nephrology and Hypertension argued that phosphate is an under-recognised contributor to blood-pressure regulation and reviewed the mineral-regulatory pathways involved (PMID 30883391). A 2017 review of gene therapy for hypertension described experimental gene-delivery strategies tested in animal models of elevated blood pressure (PMID 28780894). Both are preclinical or conceptual in scope; neither reported a human blood-pressure trial of klotho, and that gap is worth stating plainly rather than glossing (PMID 28780894).

Metabolic outcomes: insulin resistance, glucose and liver

β-klotho is the obligate co-receptor for FGF21, which is why metabolic claims attach to the klotho name. A 2020 review in Nature Reviews Endocrinology traced the therapeutic potential of FGF21 in metabolic diseases from bench to clinic, covering the translation of FGF21 biology into drug candidates (PMID 32764725). A 2021 preclinical study in EBioMedicine reported that a novel GLP-1 and FGF21 dual agonist showed therapeutic potential in models of diabetes and non-alcoholic steatohepatitis (PMID 33421947).

Directly on klotho, a 2026 review in Clinica Chimica Acta examined the relationship between klotho protein and insulin resistance (PMID 41534643). It is important to distinguish these strands: evidence that FGF21-based agents moved into clinical development is evidence about FGF21 analogues, not evidence that klotho itself was administered to humans for metabolic endpoints (PMID 32764725).

Exercise, mitochondria and the heart

A 2022 study in Circulation reported that an FGF21–sirtuin 3 axis contributed to the protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity, work conducted in experimental models rather than in people (PMID 36134579). This is frequently cited in consumer summaries as proof that klotho "mimics exercise." The study investigated FGF21 signalling and mitochondrial outcomes; extrapolating it to klotho supplementation in humans goes beyond what researchers measured (PMID 36134579).

Bone and mineral metabolism

A 2019 review in JBMR Plus covered FGF23, hypophosphatemia and emerging treatments, summarising how excess FGF23 signalling relates to phosphate-wasting disorders and the therapeutic approaches under development (PMID 31485552). Because klotho is required for FGF23 signalling at its receptor complex, the 2019 klotho review placed mineral metabolism among the core functions attributed to the protein family (PMID 30455427). Clinically approved agents in this space target FGF23, not klotho (PMID 31485552).

Aging and longevity claims

The klotho literature is closely tied to aging biology. The 2019 review discussed the klotho proteins across health and disease including age-related conditions (PMID 30455427), and the 2020 kidney review addressed klotho specifically in the context of aging (PMID 32982966). A 2018 review covered the aging kidney alongside aging-related disease more broadly (PMID 30232759).

What these papers did not report is a human lifespan or healthspan trial. Claims that klotho "extends human lifespan" are not supported by any paper cited on this page; the reviews describe mechanistic and associational work in aging biology (PMID 30455427).

Claims with thin or absent evidence in the cited literature

• Cognition and memory. No paper in this citation set measured cognitive endpoints; the reviews covered kidney, cardiovascular and metabolic biology (PMID 30455427).
• Muscle growth, skin or hair. These outcomes were not addressed in the cited reviews of klotho and the FGF23–klotho axis (PMID 37443358).
• Oral or injectable klotho as a consumer product. The clinical-stage material in this set concerns FGF21-based agents rather than klotho administration in humans (PMID 32764725).
• Blood-pressure lowering in people. Cited work was preclinical or conceptual (PMID 28780894), with phosphate-related mechanisms reviewed separately (PMID 30883391).

Klotho Safety and Adverse Events: What Studies Report

Because the cited literature contains no human interventional trial of klotho administration, there is no clinical adverse-event profile to summarise for klotho as an administered agent. The reviews instead discussed klotho as an endogenous protein and biomarker within mineral and endocrine physiology (PMID 30455427). Safety considerations that do appear in this set relate to the broader FGF axis: the 2019 review of FGF23 and hypophosphatemia discussed disorders of phosphate handling and the treatments developed for them (PMID 31485552), and the 2024 cardiology review examined pathological consequences attributed to disturbed FGF23–klotho signalling (PMID 37443358). The absence of reported adverse events is a reflection of absent trials, not of demonstrated safety.

What would strengthen the evidence base

1. Randomised human trials with prespecified kidney or cardiovascular endpoints, since current human data in this set are observational (PMID 39695774).
2. Standardised assays for circulating klotho, so that associations reported across cohorts can be compared (PMID 32982966).
3. Clear separation of klotho-specific findings from FGF21- and FGF23-targeted drug development, which has progressed further toward the clinic (PMID 32764725).

Until such data exist, the honest summary is that klotho has been studied for kidney, cardiovascular, mineral and metabolic outcomes, that most of what researchers reported came from reviews, animal experiments and association analyses, and that direct human interventional evidence was not represented in the papers cited here (PMID 30455427, PMID 39695774).

References

• The Klotho proteins in health and disease (Nature Reviews Nephrology, 2019)
• FGF23 and klotho at the intersection of kidney and cardiovascular disease (Nature Reviews Cardiology, 2024)
• The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic (Nature Reviews Endocrinology, 2020)
• Klotho, Aging, and the Failing Kidney (Frontiers in Endocrinology, 2020)
• FGF23, Hypophosphatemia, and Emerging Treatments (JBMR Plus, 2019)
• FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity (Circulation, 2022)
• Association of serum Klotho with the severity and mortality among adults with cardiovascular-kidney-metabolic syndrome (Lipids in Health and Disease, 2024)
• Gene therapy for hypertension (Expert Opinion on Biological Therapy, 2017)
• Aging Kidney and Aging-Related Disease (Advances in Experimental Medicine and Biology, 2018)
• Phosphate, the forgotten mineral in hypertension (Current Opinion in Nephrology and Hypertension, 2019)
• Klotho protein and insulin resistance (Clinica Chimica Acta, 2026)
• A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis (EBioMedicine, 2021)